Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipla Offers India Government Knowledge To Make Important Drugs

This article was originally published in PharmAsia News

Executive Summary

Cipla announced it would share with colleagues and competitors its technological knowledge about drug making as it concerns 354 drugs considered essential in India. The offer was made to discourage the government from imposing price controls on selective brands and generics. Managing Director Amar Lulla said Cipla would share its knowledge with the state-owned drug maker so the drugs could be distributed by the government through primary health care centers, medical hospitals and public health institutions at reasonable prices. Cipla has not signed on to a separate industry proposal to the government. (Click here for more

You may also be interested in...



Coronavirus Update: Russia Plans First Vaccinations In October

Concern and skepticism about Russia's rapid vaccine roll-out. Meanwhile Japan is latest to reach reaches deal with Pfizer/BioNTech.

Sun Loses Shine In Q1, Testing Times In US

Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.

QUOTED. 3 August 2020. Danielle Antalffy.

Diabetes company Dexcom said it expects 2020 revenues to reach $1.85bn driven by new patient adoption of its continuous glucose monitoring (CGM) system including by people with type 2 diabetes. See what SVB Leerink analyst Danielle Antalffy said about Dexcom’s earnings results here.

UsernamePublicRestriction

Register

LL1133273

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel